Our Latest News


Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102

--Phase I Study of ONCOS-102 in Late-stage Refractory Cancer Patients Successfully Completed and Presented at CIMT Annual Meeting-- Mainz, Germany, May 8th, 2014 - Oncos Therapeutics, Ltd., a clinical stage biotechnology company specializing in the development of targeted cancer immunotherapeutics, presented Phase I clinical data demonstrating that local administration of its lead compound, ONC...
2014-05-09 13:00
Marit Tuominen
read more